Current work in the NCI–China CDC collaboration includes a follow-up study of these industrial workers
from 1988 to 1999, updating work histories and associated exposures and disease outcomes. These data will
help refine estimates of benzene-related cancer risks and will incorporate an evaluation of factors that
determine individual susceptibility to benzene-related hematotoxicity.
These new components have included scientific input from DCEG investigators Dr. Qing Lan, Roel Vermeulen, Ph.D.,
and Bu-Tian Ji, M.D.,Dr.P.H., Dr. Graca Dores, an oncologist in NCI’s Division of Cancer Prevention, and Dr. Neal
Young, from the National Heart, Lung, and Blood Institute, have also joined the research team. In a
complementary effort, Dr. Rothman, along with Dr. Smith, from U.C. Berkeley, and Dr. Li of the China CDC,
recently carried out a crosssectional molecular epidemiology study of healthy workers exposed to relatively
low levels of benzene to evaluate the early biologic effects of benzene exposure, including
hematotoxicity, chromosomal damage, gene expression, and proteomic alterations. The team is also working
with Stephen Chanock, M.D., Meredith Yeager, Ph.D., and Robert Welch, M.S., of NCI’s Core Genotyping
Facility, to examine the influence of polymorphisms in cytokine genes on hematotoxicity in benzene-exposed
workers. In addition, Dr.Vermeulen, who leads the project’s exposure assessment component, is using
proteomic tools to study benzene’s effect on levels of certain key chemokines.
“Taken together, the cancer cohort and early effect biomarker studies have strengthened the association
between benzene exposure and the development of hematologic malignancies,” noted Dr. Hayes. “The
comprehensive and unprecedented long-term research effort between NCI and China’s CDC has played and will
continue to play a critical role in assessing the cancer risks and mechanism of action from relatively
low levels of benzene exposure.”
—Lynn Rundhaugen, M.P.H.
|
The Benzene and Cancer Study Scientific Advisory Panel, which was formed in
2002, has provided invaluable input and oversight for the benzene studies. Members are Dr. Ellen Eisen,
Chair (University of Massachusetts), Dr. David Christiani (Harvard School of Public Health), Dr. Larry
Fine (NIH), Dr. Katharine Hammond (University of California, Berkeley), Dr. Richard Hornung (University
of Cincinnati), Dr. Judith Karp (Johns Hopkins University), Dr. Noah Seixas (University of Washington),
Dr. Jack Siemiatycki (Université de Montréal), Dr. Ellen V. Sigal (Friends of Cancer Research), and Dr.
Maureen Johnson, Executive Secretary (NCI).
|
![Return to Top](nov04/top.gif)
|
![Denise Whitby Brings Viral Laboratory Expertise to DCEG](nov04/whitby.gif) |
Anyone reading about the virus behind Kaposi’s sarcoma (KS) will quickly come
across Denise Whitby’s name. But talk to her for a few minutes and you realize she’s involved in multiple
aspects of studying viral-associated cancers.
Dr.Whitby, along with a group of researchers that included Dr. Robin Weiss, who Whitby called “one of the
foremost virologists in the U.K. and Europe,” played a key role in showing that human herpesvirus-8 (HHV-8)
causes KS, a disease most common in people with AIDS. Dr.Whitby and others did some of the most
significant early studies on KS and HHV-8 (now also called KSHV, for Kaposi’s sarcoma-associated
herpesvirus).
Dr.Whitby, a native of England, received her Ph.D. at the Institute of Cancer Research in London and
trained in Weiss’ lab there. “I developed an interest in disease associations and epidemiology,” she
said. “The opportunity to run a virology lab in association with an epidemiology group is what brought
me to NCI.”
As laboratory director of the Viral Epidemiology Section, located at NCI–Frederick, Dr.Whitby wears
several hats. She oversees the core support that the lab provides for studies within DCEG. The lab
performs routine serology and molecular studies of viruses known or thought to be associated with cancer.
In the few years she has been at NCI, Dr. Whitby has helped effect many changes in the lab. “When I
arrived, most of the work was done using commercial kits and was very routine,” she said. “Since I’ve
been here, we’ve developed in-house assays that are more suited to the needs of the Viral Epidemiology
Branch.Many of the assays are more complex, so the 4 DCEG Linkage nature of what we’re doing is more
cutting edge.”
Also, she said, the lab has developed real-time PCR assays to quantify viral DNA or RNA in clinical
samples. “We’re also involved in doing gene expression arrays, both viral and human,” she said. Dr.
Whitby’s interest in the genotyping and evolution of HHV-8 has meant that the lab now has expertise in
these areas and can transfer techniques to studies of other viruses.
“We’re currently developing an oncoviral chip,” she said. “We’re going to express oligonucleotides from
all viruses associated with cancer, including both human and animal viruses.We will use this chip to
screen for both known and unknown agents; there should be some binding if there is a related but as yet
unknown virus.”
Dr.Whitby is a principal investigator in the Epidemiology and Biostatistics Program. Her research there
continues to focus on KS, particularly aspects of transmission, environmental cofactors for transmission
and disease, and the evolution of KSHV.
She is also looking to expand her horizons a bit. “I’m increasingly interested in viral causes of
lymphoma and in searching for new viruses that may be associated with cancer,” she noted. “In the lab, we
hope to continue to develop scalable assays that are suitable for epidemiologic research, depending on
the needs of the studies we’re presented with...I also want to continue my own studies, with perhaps a
greater emphasis on the lymphoma work and searching for new viruses associated with cancer.”
—Nancy Volkers
|
![Return to Top](nov04/top.gif)
|
![DCEG Fellows Begin Colloquium Series](nov04/series.gif) |
DCEG fellows organized and initiated a new series of monthly lectures beginning in
spring 2004 as a means to foster interaction and communication of research among fellows in the Division.
The idea for a DCEG Fellows Colloquium series grew from suggestions at the Fellows’ Town Hall Meeting. “Colloquium”
derives from a Latin word meaning “to talk together” and describes an informal meeting for the exchange of
views. In this spirit, the series was originally conceived as a forum for fellows to present their research in a relaxed
collegial atmosphere, to learn about the research being carried out by other fellows within the Division,
and to facilitate opportunities for informal scientific interactions. It has since expanded to include
featured presentations on statistical techniques and methods, particularly in areas that are quickly evolving, such
as molecular genetics.With the support of DCEG’s Office of Education (OE), the series is run by the fellows
for the fellows, who set the agenda, recruit speakers, and ensure that relevant topics are discussed.
Planning for the colloquia rotates among the branches, which allows not only shared responsibility but ensures
that a broad range of topics are included. It also allows fellows from all areas of DCEG to present their
research.
The Colloquium series kicked off on April 19, 2004, with approximately 35 fellows in attendance. The
Nutritional Epidemiology Branch (NEB) volunteered to be responsible for the first three meetings, with
Shih-Chen Chang, Ph.D., and Unhee Lim, Ph.D., taking the lead. At the April and May meetings, fellows
gathered to introduce themselves and talk about their research in DCEG. From these interactions, a Fellows’
Research Network was established that lists all the projects in which fellows are involved. This directory
will serve as a resource to foster collaboration among fellows across the Division. In June, the
Colloquium featured presentations by Jinbo Chen, Ph.D., Mitchell Gail, M.D., Ph.D., and Ruth Pfeiffer,
Ph.D., of the Biostatistics Branch on the use of risk prediction models.
Robin Wilson, Ph.D., Occupational and Environmental Epidemiology Branch (OEEB), organized the next series
of meetings. The July Colloquium, led by Kenneth Adams, Ph.D. (NEB), Sonja Berndt, Pharm.D. (OEEB), Beth
Brown, Ph.D. (Viral Epidemiology Branch), and Sarah Daugherty, M.P.H. (OEEB), provided an introduction to
haplotype analysis. The DCEG Haplotype Interest Group continued the discussion of genetic data analysis
during the September meeting. In October, Dr. Brown spoke on “The Finer Points of Presentations Using
PowerPoint.”
“This has been a fantastic development, one that I believe will greatly further our concept of a
‘community of fellows’ and benefit them directly,” remarked Demetrius Albanes, M.D., Chief of DCEG’s OE.
“In addition to serving as a venue for information and knowledge sharing, it is providing opportunities
for comradery, leadership, and creativity. The energy and time they have put into the colloquia reflect
not only their enthusiasm and commitment to the scientific research but to continued learning.”
—Laura Beane-Freeman, Ph.D. and Deirdre Hill, Ph.D.
|
IRVA HERTZ-PICCIOTTO GIVES DISTINGUISHED LECTURE
Dr. Irva Hertz-Picciotto, a professor in the Department of Epidemiology and
Preventive Medicine at the University of California, Davis, was recently honored as the DCEG Distinguished
Lecturer in Occupational and Environmental Cancer. During her June 3rd visit, Dr. Picciotto spoke on “The
case-control study, causal inference, and the assessment of validity” and presented a practical method
for assessing and correcting for selection bias. Dr. Picciotto received her Ph.D. in epidemiology from the
University of California, Berkeley. Her research has focused on environmental exposures, pregnancy
outcomes, and epidemiologic methods. Her notable career includes service on scientific advisory boards
for the State of California, the U.S. Environmental Protection Agency, and the National Institute of
Environmental Health Sciences.
The Distinguished Lecture series, which began in 2002, is sponsored by DCEG’s Occupational and
Environmental Epidemiology Branch. More information is available at
http://dceg.cancer.gov/oeeb/about/events.
|
![Return to Top](nov04/top.gif)
|
![Aaron Blair Wins John Goldsmith Award](nov04/award.gif) |
Aaron Blair, Ph.D., of the Occupational and Environmental Epidemiology Branch
(OEEB), received the 2003 John Goldsmith Award for Outstanding Contributions to Environmental Epidemiology.
The award is presented by the International Society for Environmental Epidemiology (ISEE) in honor of
Goldsmith, one of the organization’s founders and early leaders. It recognizes environmental epidemiologists
who serve as role models for excellence in research, unwavering promotion of environmental health, and
integrity. Dr. Blair accepted the award at ISEE’s annual meeting, held in August in New York City.
“Dr. Blair has led a productive group of researchers at NCI whose high-quality epidemiologic
studies have often raised the bar in their innovative approaches to exposure assessment.”
Although Dr. Blair holds a doctoral degree in evolutionary genetics, he became interested in cancer
epidemiology while doing postdoctoral work in heart disease at the University of North Carolina at Chapel
Hill. He arrived at NCI in 1976 and for more than 20 years has led OEEB’s research program. The Branch’s
early research focused primarily on occupational exposures; however, under Dr. Blair’s guidance, the Branch
gradually expanded to incorporate environmental epidemiology. Dr. Blair’s personal research includes
landmark studies of industrial workers exposed to formaldehyde, acrylonitrile, and other chemicals, as well
as studies of exposure to pesticides and solvents in the workplace and in the general environment.
Dr. Blair has long championed multidisciplinary and collaborative approaches to Branch projects. In the
early days of the Branch, he recruited industrial hygienists to work closely with epidemiologists on
occupational studies to develop improved methods of exposure assessment, and he extended this approach to
measure exposures in the general environment. Current Branch projects often incorporate sophisticated
exposure assessment, biological components for mechanistic evaluation, and intensive collaboration among
epidemiologists, molecular biologists, industrial hygienists, environmental engineers, and geographers.
“Dr. Blair has long been a prolific researcher in the area of environmental and occupational cancer
epidemiology,” noted Dr. Irva Hertz-Picciotto, pastpresident of ISEE and chair of the John Goldsmith Award
committee.
Dr. Blair has authored more than 200 publications on occupational and environmental causes of cancer and
serves on the editorial boards for the more than a dozen journals. He is an elected board member of the
American College of Epidemiology and the recipient of the NIH Director’s Award, the U.S. Public Health
Service Special Recognition Award, the U.S. Department of Health and Human Services Quality of Work Life
Award, the DCEG Exemplary Service Award, and the University of North Carolina H.A. Tyroler Distinguished
Alumni Award. He was recently elected as a fellow in the Collegium Ramazzini.
In her comments at the ceremony, Dr. Hertz-Picciotto summed up the reasons for ISSE’s choice of Dr. Blair:
“He has led a productive group of researchers at NCI whose high-quality epidemiologic studies have often
raised the bar in their innovative approaches to exposure assessment. Moreover, his exceptional mentoring of
predoctoral and postdoctoral students has contributed enormously to the next generation of environmental
epidemiologists. In the eyes of the International Society of Environmental Epidemiology, these
accomplishments have earned Dr. Blair the John Goldsmith Award.”
|
![Return to Top](nov04/top.gif)
|
![Conference Considers Radiation In Realistic Environments](nov04/radiation.gif) |
In June, the American Statistical Association held its 16th conference on Radiation
and Health in Beaver Creek, Colorado. Ethel Gilbert, Ph.D., of the Radiation Epidemiology Branch (REB),
cochaired the conference with Dr. David Brenner of Columbia University. The conference, Radiation in
Realistic Environments, examined interactions between radiation and other factors, such as smoking and
genetics. Approximately 60 investigators from various disciplines and workplaces attended from the United
States, Canada, the United Kingdom, and Australia.
Four DCEG fellows received Young Investigator Awards to travel to and participate in the meeting: Alina
Brenner, M.D., Ph.D. (REB), Michael Hauptmann, Ph.D. (BB), Preetha Rajaraman (REB), and Cecile Ronckers, Ph.D.
(REB).
Invited REB speakers included Ruth Kleinerman who spoke on “Geneenvironment interactions in irradiated
retinoblastoma patients”; Lois Travis, M.D., Sc.D., on “Lung cancer following Hodgkin lymphoma”; and Alice
Sigurdson, Ph.D., on “Second cancers after radiotherapy: Any evidence of radiation-induced genomic
instability?”
The conference offered a unique forum for discussing the qualitative aspects of radiation health research
in a multidisciplinary setting. Attendees had the opportunity to participate in a wide variety of
discussions, for example, on whether radiation doses below one rad increase cancer risks, and the complexities
in determining the risks and benefits of undergoing screening for breast and lung cancer.Many presentations
focused on the carcinogenic effects of radiation exposures and the role of population variations in DNA
damage and pathway disruption (e.g., protein-complex modification in homologous recombination or
non-homologous end-joining and breast cancer). There were also presentations about the role of ATM gene
mutations in the sensitivity of the esophagus to radiation and to the current status of radioprotectants.
|
REB SCIENTISTS TALK ON APPLICATIONS OF RADIATION DOSIMETRY IN EPIDEMIOLOGY AT NATIONAL MEETING
On July 13, 2004, in Washington, DC, the Radiation Epidemiology Branch
(REB) held a special NCI-sponsored session at the 49th annual meeting of the Health Physics Society, the
world’s largest society of radiation protection specialists. The session, organized by Steve Simon, Ph.D.,
of REB, highlighted the “Uses of radiation dosimetry in epidemiologic studies.” Dr. Simon and REB
Scientist Andre Bouville, Ph.D., cochaired the four-hour session of 12 presentations.
The papers presented in the session are now being prepared for publication in a special issue of the journal
Radiation Research. The first presentation, by Martha Linet, M.D., Chief of REB, was an overview of the
role of dosimetry in epidemiologic studies of cancer. Next was a presentation by Dr. Simon on
“Dosimetric requirements for epidemiologic studies.” Other talks from REB staff were given by Dr.
Bouville and Nickolas Luckyanov, Ph.D., who discussed applications of dosimetry in epidemiologic studies
of nuclear testing and the Chornobyl nuclear accident. Ruth Kleinerman, also from REB, spoke on the
emerging field of retrospective assessment of exposure using biological dosimetry, and Ethel Gilbert,
Ph.D., discussed the statistical ramifications of dose uncertainties in radiation dose-response analyses.
The session topic, while outside the experience of most applied health physicists, was wellattended and
added a new dimension to the conference. “The presentations were terrific, easy to follow, and not
repetitive,” noted Dr. Linet. “I was pleased to see that this session was so well-received.”
|
![Return to Top](nov04/top.gif)
|
![DCEG Staff Volunteer at Camp Fantastic](nov04/camp.gif) |
About 60 miles west of NIH, near Winchester,Virginia, in the foothills of the Blue
Ridge Mountains, there’s a very special camp for children with cancer. Camp Fantastic, which is run by the
organization Special Love, is a week-long, residential summer camp held every August. The camp is
supported by an NCI clinical protocol, which provides medical and nursing staff for the full week.
The camp holds special meaning for the three DCEG staff members who volunteer with the program. Stephen
Chanock, M.D., Larry Chloupek, and Sheree Hawkins all treasure the time they spend working on the Camp
Fantastic program and continually find inspiration in the campers.
Dr. Chanock’s NCI duties include directing the Core Genotyping Facility and serving as a senior investigator
in the Pediatric Oncology Branch. He has been involved with Camp Fantastic since 1992, and in 1996 he became its medical director.
He also serves on the Special Love board of directors.
Mr. Chloupek, who is Deputy Manager in DCEG’s Administrative Resource Center (ARC), has been volunteering
at Camp Fantastic since 1989. His passion is directing the camp’s program for young adult cancer patients.
He also serves on the board of directors and participates in numerous camp events throughout the year. Mr.
Chloupek, who is also a cancer survivor, was introduced to Special Love while volunteering for the American
Cancer Society. One of the society’s volunteers suggested that Mr. Chloupek call the organization,
believing that his skills and experiences would truly benefit Special Love. It has turned out to be a
perfect match. “I really feel my experience as a cancer survivor can serve as a role model for those
individuals who are going through this experience,” said Mr. Chloupek. “I can provide a concrete example
that one can go through this type of experience, survive, and continue to lead a productive life.”
Ms. Hawkins, who is an Administrative Officer in DCEG’s ARC, has been volunteering with Camp Fantastic
since 1999 and helps out year-round with the massive amounts of logistical work needed to run the camp,
including having all campers placed on protocol, getting outside medical staff credentialed, and transporting
medications and other necessary supplies back and forth during camp week.
Started in 1983, Camp Fantastic is Special Love’s hallmark program, offering a week of classes,
recreation, theme parties, campfires, and other exciting activities for 7- to 17-year-old cancer patients
who are currently being treated or who finished treatment within the past three years. To read more about
Camp Fantastic, go to www.speciallove.org. Contributions to Special Love can be made through the combined
federal campaign.
—Maria Sgambati, M.D.
|
HREB LAUNCHES DISTINGUISHED LECTURER SERIES
The Hormonal and Reproductive Epidemiology Branch (HREB) recently
established a distinguished lecturer series, which will serve as a platform for outstanding scientists
in the extramural community to provide input into DCEG studies on hormones and cancer. The inaugural scholar,
Dr. Frank Stanczyk, Professor of Preventive Medicine at the University of Southern California, visited
DCEG for three days in June. He gave a provocative seminar entitled “Measurements of steroid hormones in
epidemiologic studies of breast and prostate cancers: What is missing?” Dr. Stanczyk reviewed the formation, metabolism, and clearance of sex steroids in both men and women, and he discussed
pitfalls in the measurement of steroid hormones. He pointed out that the lack of reliable immunoassays to
quantify steroids in serum, urine, or tissue is a major deficiency in epidemiologic studies, and he
questioned the reliability of the direct immunoassays used to quantify urinary 2-hydroxyestrone and
16 alpha-hydroxyestrone.
He challenged epidemiologists to consider measuring complete androgen/estrogen profiles and relevant
metabolites in serum and tissue, particularly using gas chromatography or liquid chromatography-mass
spectrometry, tools for peering into the structure of molecules by separating them based on size and
charge. He also called attention to potentially important metabolites, such as androstenedione, 5
alphaandrostanedione and DHT sulfate, which have not been measured in epidemiologic studies. Dr.
Stanczyk also presented new data suggesting interactions between sex steroids and cytokines.
Dr. Stanczyk is an internationally recognized authority on the metabolism, pharmacokinetics, and measurement
of steroid hormones, and he has collaborated extensively on epidemiologic studies with scientists at
several cancer centers and universities as well as those at NCI.
—Ann Hsing, Ph.D.
HPV VACCINE STUDY LAUNCHES
NCI researchers, in conjunction with the Foundation for the Costa Rican
Institute for Research and Training in Nutrition and Health (Fundación INCIENSA), have begun to recruit participants
for a Phase III trial to evaluate whether a vaccine can protect women against infection and disease
caused by two types of human papillomavirus (HPV) that are known to cause cervical cancer.
The study, which is taking place in Guanacaste, Costa Rica, is testing an HPV 16/18 virus-like particle
vaccine whose technology was originally discovered at NCI and which is now being manufactured for the
trial by GlaxoSmithKline Biologicals. The trial is a collaboration between NCI researchers, led by Allan
Hildesheim, Ph.D., of DCEG’s Hormonal and Reproductive Epidemiology Branch, and a team of over 100
researchers from the Fundación INCIENSA, headed by Dr. Rolando Herrero. Investigators hope to collect
additional information on the vaccine’s safety, how well it stimulates the immune system to fight HPV
infection, and how effective it is at preventing the lesions that are precursors to cervical cancer.
Cervical cancer is one of the most common cancers among women worldwide. Approximately 500,000 women
are diagnosed with cervical cancer each year, and more than 200,000 women die from the disease annually.
Guanacaste, Costa Rica, was chosen for this study because of its high rate of cervical cancer and the
many years of collaboration between NCI and the Costa Rican research team, which have resulted in an
extensive knowledge of the natural history of the disease in the area.
Between 12,000 and 15,000 women, aged 18 to 25 years, will be randomized to receive the HPV 16/18
vaccine or a control vaccine. These two HPV types account for 60 to 70 percent of all cervical cancers.
The vaccine is a result of decades of NCI research with Costa Rican collaborators, which causally linked
HPV infection with anogenital tumors. Previous human trials in the United States led to the development
of improved techniques for cervical cancer screening and to this preventive vaccine.
Study participants will receive three doses of the vaccine over a six-month period and will be followed
for four years to see whether the vaccine can protect against known precursor lesions and to determine
how long the vaccine protects women. Less than two months after the trial was launched, more than 800
participants had already enrolled. The NCI Principal Investigator Dr. Hildesheim comments, “I have to say
that seeing a study of this magnitude launched after so many years of careful planning has been quite an
experience!”
—Cari Kornblit
|
![Return to Top](nov04/top.gif)
|
![DCEG Summer Program Continues To Attract Top Students](nov04/summer.gif) |
DCEG once again had a highly successful summer student program. Between November and
May, the Office of Education (OE) received more than 200 applications and ultimately accepted 18 students
for the program. The class comprised a diverse group that represented different stages of education and
included high school, undergraduate, and graduate students.
The 2004 program featured very gifted students, many of whom received selective grants and awards that
enabled them to come to DCEG. Jacqueline Sequoia, a first-year Master of Public Health student at San Diego
State University who worked in the Nutritional Epidemiology Branch (NEB) with Margaret Wright, Ph.D., and
Demetrius Albanes, M.D., successfully competed for the highly selective NCI fellowship program, Introduction
to Cancer Research Careers (ICRC), which is sponsored by the NCI’s Office of Diversity and Employment
Programs and Center to Reduce Cancer Health Disparities. “I am very excited that I will be learning how to
write manuscripts for publication, and I intend to use my summer research for my M.P.H. thesis,” said Ms.
Sequoia, in describing how she has benefited from the summer program.
"We encourage DCEG staff at all levels to seriously consider offering rewarding summer
internships to bright and enthusiastic students … It has become clear that such early exposure to our
field of research often leads to further training in epidemiology and the commitment to discovering
the causes of cancer."
Chuankai Michael Pan, a graduate of Winston Churchill High School who recently received a Robert Wood
Johnson Foundation Young Epidemiology Scholar award for research he conducted during the 2003 summer program
(Linkage July 2004), returned to DCEG this summer to continue his analyses on smoking in relation to
gallstone disease and gallbladder cancer.
The summer program would not be successful without the dedicated participation of mentors. The mentoring
relationship allows students to gain knowledge by shadowing their mentors and participating in projects. “I have
gained tremendous experience by taking part in the everyday activities in the world of cancer epidemiology,”
said Sara Schonfeld, a first-year graduate student from George Washington University who worked with Lois
Travis, M.D., Sc.D., in the Radiation Epidemiology Branch. “This experience has been incredibly helpful in
learning to see the ‘big picture’ of epidemiologic research.”
Typically, more advanced scientists mentor summer students. But this year, three postdoctoral fellows—
Margaret Wright, Ph.D. (Nutritional Epidemiology Branch), Tanuja Rastogi, Sc.D. (NEB), and Sam Mbulaiteye,
M.D. (Viral Epidemiology Branch)—served as mentors. Sponsoring a summer student is an excellent way for
fellows to gain experience in mentoring and to share their growing skills. “It has been a great experience
to guide a summer student,” said Dr. Mbulaiteye. “It improved my appreciation of what mentoring is all about.”He
recommends that other fellows give mentoring a try but advises them to make sure they have a project the
student can start right away and complete during the summer.
“We encourage DCEG staff at all levels to seriously consider offering rewarding summer internships to
bright and enthusiastic students,” said Dr. Albanes, who also serves as Chief of the OE. “It’s become clear
that such early exposure to our field of research often leads to further training in epidemiology and the
commitment to discovering the causes of cancer.”
Kristin Kiser, M.H.A. (OE), who helped coordinate this year’s successful program, will be accepting
applications for the 2005 summer beginning in November 2004.More information about the summer program can
be found at the DCEG web site: http://dceg.cancer.gov
—Erin McGuigan
|
SUMMER STUDENTS AND MENTORS
BIOSTATISTICS BRANCH
- Ronald Hsu, Harvard University. Mentor: Philip Rosenberg, Ph.D.
- Jiunzhu “Jane” Li, University of Maryland and University of Michigan. Mentor: Barry Graubard, Ph.D.
CLINICAL GENETICS BRANCH
- Heather Bremer, University of Maryland. Mentor: June Peters, M.S., C.G.C.
- Barbara Choo, San Jose State University. Mentor: Jennifer Loud, M.S.N., C.R.N.P. Poster: Ductal lavage: Tolerability in women at high genetic risk of breast cancer.
- Kelly Yu, Johns Hopkins School of Public Health. Mentors: Neelam Giri, M.D., and Blanche Alter, M.D. Poster: Clinical profile of the NCI Fanconi’s anemia cohort.
GENETIC EPIDEMIOLOGY BRANCH
- Eitan Bernstein, Charles E. Smith Jewish Day School. Mentors: Jorge Toro, M.D., and Ousmane Toure, Ph.D. Poster: Inactivation of the Fumarate Hydratase Gene in tumors associated with Hereditary Leiomyomatosis Renal Cell Cancer.
- Shannon Gnall, University of North Carolina, Wilmington. Mentor: Neil Caporaso, M.D.
- Ouqi Jiang, Massachusetts Institute of Technology. Mentors: Jorge Toro, M.D., and Ousmane Toure, Ph.D.
NUTRITIONAL EPIDEMIOLOGY BRANCH
- Brook Calton, Johns Hopkins School of Public Health. Mentor: Michael Leitzmann, M.D., Dr.P.H. Poster: Physical activity and colon cancer risk among women: A prospective cohort study. Roy Kao, Brown University. Mentor: Tanuja Rastogi, Sc.D. Poster: Comparison of cancer survival among Asian Indians and Pakistanis and other races in the United States.
- Jacqueline Sequoia, San Diego State University School of Public Health. Mentors: Demetrius Albanes, M.D., and Margaret Wright, Ph.D. Poster: A prospective investigation of height and prostate cancer risk in male smokers.
OCCUPATIONAL AND ENVIRONMENTAL EPIDEMIOLOGY BRANCH
- Tiffany Jones, Tougaloo College. Mentors: Lee Moore, Ph.D., and Robin Wilson, Ph.D.
- Laurie Gold, Emory School of Public Health. Mentors: Mary Ward, Ph.D., and Roel Vermeulen, Ph.D.
- Chuankai Michael Pan, Winston Churchill High School. Mentors:Wong Ho Chow, Ph.D., and Bu-Tian Ji, M.D., Dr.P.H.
RADIATION EPIDEMIOLOGY BRANCH
- Sara Schonfeld, George Washington University. Mentor: Lois Travis, M.D., Sc.D. Poster: Second non-germ cell solid tumors among long-term survivors of testicular cancer.
VIRAL EPIDEMIOLOGY BRANCH
- Brandon Brown, University of California, Irvine. Mentor: Michie Hisada, M.D., Ph.D., Sc.D. Poster: Cytokine gene polymorphisms and risk of human T-lymphotropic virus type I infection in Jamaican children.
- Laura Fraade-Blanar, Johns Hopkins University School of Public Health. Mentor: Eric Engels, M.D. Poster: AIDS-Associated Kaposi Sarcoma in Seattle, Washington and New York City: An examination of predictors based on the AIDS-Cancer Match Registry.
- Meklit Workneh, Stanford University. Mentor: Sam Mbulaiteye, M.D. Poster: Risk for AIDS and non-AIDS-defining cancers among persons with HIV/AIDS in Uganda: Results from the Uganda AIDS-Cancer Match Registry Study.
|
![Return to Top](nov04/top.gif)
|
![International Workshop on Biliary Cancer Showcases New Findings](nov04/workshop.gif) |
The Biliary Tract Cancer International Workshop, which was held in July 2004 in
Shanghai, China, drew more than 150 scientists, including most of the world’s experts in this field. The
workshop was the culmination of a long-term collaboration between NCI and the Shanghai Cancer Institute
(SCI) and showcased new results from a four-year populationbased study of biliary tract cancer, the largest
and most comprehensive study ever conducted on this malignancy (Linkage, March and September 2002). Ann
Hsing, Ph.D. (Hormonal and Reproductive Epidemiology Branch), and Dr. Yu-Tang Gao (SCI) served as cochairs.
The workshop received sponsorship from NCI, SCI, the NIH Office of Rare Diseases, and the Shanghai Medical
Association.
Participants included investigators from disciplines such as epidemiology, pathology, surgery,
gastroenterology, genetics, and molecular biology. Held over 2 days, the workshop included presentations,
panel discussions, and a poster session. Several DCEG scientists presented the results of their research,
reporting positive associations of biliary tract cancer with gallstones, obesity, parity, cholecystitis,
chronic infection with hepatitis B virus, family history of gallstones, and consumption of preserved foods
as well as an inverse association with use of nonsteroidal anti-inflammatory drugs. Genetic variants of
apolipoprotein E, estrogen receptor, and DNA repair genes were also associated with excess risk of biliary
tract cancer in China.
Dr. Albert Lowenfels of New York Medical College, the keynote speaker, gave an insightful overview of risk
factors for biliary tract cancer and emphasized the need for interdisciplinary approaches to improve our
understanding of the causes of this often-fatal cancer. The remainder of the two days was devoted to a wide
range of topics, including demographic patterns; risk factors; clinical management; loss of heterozygosity
and other measures as tools for early diagnosis; possible role of microbial agents, including hepatitis
viruses and Helicobacter species; identification of molecular targets for diagnosis and therapy; genetic
and epigenetic factors in gallstones and biliary tract cancer; and high-throughput approaches to identifying
cancer susceptibility genes. The workshop committee is planning a meeting summary to be submitted for
publication in a peer-reviewed journal. The workshop closed with a think-tank session whose participants
were charged with making recommendations for future scientific research; a consensus was reached to form a
consortium of investigators to forge and facilitate interdisciplinary collaboration.
—Ann Hsing, Ph.D.
|
![Return to Top](nov04/top.gif)
|
![Scientific Highlights](nov04/highlights.gif) |
BLADDER CANCER
Disinfection By-products and Bladder Cancer (full
text)
Disinfection by-products in drinking water may increase the risk of bladder cancer. The data from six
case-control studies of bladder cancer that used trihalomethanes as a marker of disinfection by-products
were pooled and analyzed (see Figure 1). Among 2,806 cases and 5,254 controls, a higher risk was seen in
men exposed to an average of more than 1 microg/L (ppb) trihalomethanes than in those who had lower or no
exposure (odds ratio [OR] = 1.2; confidence interval [CI] = 1.1–1.4). Estimated relative risks increased
with increasing exposure and strengthen the hypothesis that the risk of bladder cancer is increased
with long-term exposure to disinfection by-products at concentrations currently observed in many
industrialized countries. (Villanueva CM, Cantor KP, Cordier S, Jaakkola JJ, King WD, Lynch CF, Porru
S, Kogevinas M. Disinfection byproducts and bladder cancer: A pooled analysis. Epidemiology
2004;15:357-367)
BREAST CANCER
Breast Cancer Rates Vary by Histopathology (full
text)
Age-specific incidence rate patterns for different morphologic types of breast cancer were compared using
records from the SEER (Surveillance, Epidemiology, and End Results) Program registries. Age-specific
incidence rate curves showed three dominant patterns: (1) rates for infiltrating duct carcinoma of no special
type (duct NST), tubular, and lobular carcinomas increased rapidly until age 50 years, then rose more
slowly; (2) rates for medullary and inflammatory breast carcinomas increased rapidly until age 50 years,
then failed to increase; and (3) rates for papillary and mucinous carcinomas increased steadily at all
ages. The patterns varied by estrogen receptor expression and suggest that menopause has a greater
impact on medullary and inflammatory carcinomas than on duct NST, tubular, and lobular carcinomas and
perhaps no effect on papillary or mucinous carcinomas. (Anderson WF, Chu KC, Chang S, Sherman ME.
Comparison of age-specific incidence rate patterns for different histopathologic types of breast
carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:1128-1135)
Probability of Death from Breast Cancer (full
text)
Data on breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) Program were
used in a competing-risk analysis to examine probabilities of death from breast cancer and other causes.
Cause of death was determined for 395,251 white and 35,259 black female breast cancer patients. The
probability of death (see Figure 2, page 14) from breast cancer versus other causes varied substantially
depending on stage, tumor size, estrogen receptor status, and age at diagnosis in both white and black
patients. (Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and
other causes among female breast cancer patients. J Natl Cancer Inst 2004;96:1311-1321)
CERVICAL CANCER
p16INK4a as a Prognostic Marker in Cervical HPV Infection (full
text)
The use of p16INK4a immunostaining as a potential diagnostic and prognostic biomarker for cervical
neoplasia was explored using paraffin-embedded tissue blocks obtained from women referred for colposcopy
during the enrollment phase of the Guanacaste Project in Costa Rica. The study group included 292
women selected by HPV (human papillomavirus) status (HPV negative, nononcogenic HPV positive, or
oncogenic HPV positive) and representing the diagnostic spectrum from normal to precancer, defined as
cervical intraepithelial neoplasia (CIN). For CIN3, the sensitivity and specificity of diffuse p16INK4a
immunostaining were 100 and 95 percent, respectively. For CIN2, the sensitivity and specificity for
diffuse staining were 81.1 and 95.4 percent, respectively. Generalized to the 10,000-woman cohort, this
translated to positive predictive value and negative predictive value of 13.9 percent and 100 percent,
respectively, for CIN3, and 20.4 percent and 99.7 percent, respectively, for CIN2 or CIN3. Among women
with an initial diagnosis of less than CIN2, 44 percent with diffuse staining developed persistent
infection at five to seven years of follow-up. (Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME,
Burk RD, Hildesheim A, Bratti MC, Wright T, Rodriguez AC, Chen S, Reichert A, von Knebel Doeberitz C,
Ridder R, von Knebel Doeberitz M. Validation of p16INK4a as a marker of oncogenic human papillomavirus
infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol
Biomarkers Prev 2004;13:1355-1360)
COLORECTAL ADENOMAS
Meat Intake and the Recurrence of Colorectal Adenomas (full
text)
A large randomized controlled trial was reassessed to evaluate whether reduced meat intake was
associated with recurrence of adenomatous polyps of the large bowel, precursors of most colorectal
malignancies. All subjects (n = 1905; 958 interventions and 947 controls) had one or more colorectal
adenomas removed during a colonoscopy within 6 months before randomization. In the intervention group,
the reduction in median meat intake was 30 percent and 31 percent for men and women, respectively, by the
end of the first year. The analysis provided no evidence that lower intake or reduction in red meat
consumption over four years reduces the risk of adenoma recurrence, whereas high intake of fish was associated
with lower risk of adenoma recurrence. (Mathew A, Sinha R, Burt R, Caan B, Paskett E, Iber F, Kikendall W,
Lance P, Shike M,Weissfeld J, Schatzkin A, Lanza E. Meat intake and the recurrence of colorectal adenomas.
Eur J Cancer Prev 2004;13:159-164)
GASTRIC CANCER
Diet and Stomach Cancer Risk (full
text)
A case-control study of residents diagnosed with stomach cancer during 1994 to 96 (n = 274) and controls (n = 463)
from the general population was conducted in Warsaw, Poland, which has elevated rates of this cancer.
Using data from direct interviews on food and beverage consumption, risk of stomach cancer was inversely
related to intake of total fruits and dark green-yellow vegetables and to indices of vitamins C and E and
alphaand beta-carotenes. However, risk was not significantly increased among those with high intake of
pickled/salted vegetables and sausages. Risks were positively associated with increased intake of breads/cereals/rice/pasta
and other refined grains as well as a high carbohydrate index. Our findings add to the evidence of a
protective effect of fruits and certain vegetables on risk of stomach cancer but do not indicate that high
intake of preserved foods like sausage has contributed to the country’s elevated incidence of stomach
cancer. (Lissowska J, Gail MH, Pee D, Groves FD, Sobin LH, Nasierowska-Guttmejer A, Sygnowska E,
Zatonski W, Blot WJ, Chow WH. Diet and stomach cancer risk in Warsaw, Poland. Nutr Cancer
2004;48:149-159)
GENETICS
Somatic KIT Mutations in Familial Testicular Cancer (full
text)
Somatic mutations of the KIT gene have recently been reported in mediastinal and testicular germ cell
tumors (TGCTs), particularly in cases with bilateral disease. The KIT coding sequence (except exon 1) was
screened for germline mutations in 240 pedigrees with two or more cases of TGCT identified in an
international consortium. Although no germline mutations were found, exons 10, 11, and 17 of KIT were
examined for somatic mutations in 123 TGCT from 93 multiple-case testicular cancer families. Five somatic
mutations were identified; four were missense aminoacid substitutions in exon 17 and one was a 12 bp
in-frame deletion in exon 11. Two of seven TGCT from cases with bilateral disease carried KIT mutations,
versus three out of 116 unilateral cases (p = 0.03). Somatic KIT mutations are implicated in the development
of a minority of familial as well as sporadic cases of TGCT. (Rapley EA, Hockley S,Warren W, Johnson L,
Huddart R, Crockford G, Forman D, Leahy MG, Oliver DT, Tucker K, Friedlander M, Phillips KA, Hogg D,
Jewett MA, Lohynska R, Daugaard G, Richard S, Heidenreich A, Geczi L, Bodrogi I, Olah E, Ormiston WJ,
Daly PA, Looijenga LH, Guilford P, Aass N, Fossa SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H,Weber
W, Einhorn L,Weber BL, McMaster M, Greene MH, Bishop DT, Easton D, Stratton MR. Somatic mutations of KIT
in familial testicular germ cell tumours. Br J Cancer 2004;90:2397-2401)
Risk of Head and Neck Cancer in Transplanted and Untransplanted Patients with Fanconi Anemia (full
text)
Fanconi anemia (FA) patients have a high baseline risk of squamous cell cancers of the head, neck, and
esophagus (SCC). Hematopoietic stem cell transplantion, the only therapy that can restore hematopoiesis in
patients with FA, may increase SCC incidence.We evaluated the risks of SCC and death in 145 untransplanted
FA patients in the North American Survey (NAS) cohort and 117 transplanted FA patients in the French
Hopital Saint Louis (SLH) cohort. The age-specific hazard of SCC was 4.4-fold higher in transplanted than
untransplanted FA patients (p = 0.003), and SCC occurred at significantly younger ages in the former
(respective medians: 18 and 33 years, p = 0.004). Survival after SCC was similarly poor in both cohorts
(p = 0.135, median = 13 months). The hazard of SCC increased at a greater than linear rate, to 4.4%/year
by age 40 in NAS and 4.7%/year by 10 years after transplant in SLH. Acute and chronic graft- versus-host
diseases were significant SCC risk factors. (Rosenberg PS, Socie G, Alter BP, Gluckman E. Risk
of head and neck squamous cell cancer and death in transplanted and untransplanted
patients with Fanconi anemia.
Blood 2004; August 26, electronic publication before print)
Risk of Cancer in CDKN2A Mutation Carriers
The CDKN2A gene is the major known high-risk melanoma susceptibility gene and may increase risk for other cancers
as well. Risk of nonmelanoma cancer was examined in 117 mutation-positive and 136 mutation-negative
members from 15 families that had at least two first-degree relatives with melanoma and CDKN2A mutations.
The families have been followed prospectively for 4 to 26 years starting in the 1970’s. No significant
association was seen for mutationnegative subjects (Obs/Exp = 0.3; CI = 0.0–1.2), although this group had
only two observed cancers. In contrast, mutation-positive subjects had a significantly increased risk for
all cancers combined (Obs/Exp = 12/5.5 = 2.2; CI = 1.1–3.8) primarily because of digestive system tumors,
particularly pancreatic cancer. (Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA.
Prospective risk of cancer in
CDKN2A germline mutation carriers. J Med Genet 2004;41:421-424)
HEMATOPOIETIC MALIGNANCIES
Familial Aggregation of Hodgkin Lymphoma
To better understand the importance of genetic factors, age, and gender on the etiology of Hodgkin
lymphoma (HL), diagnoses of all lymphoproliferative malignancies were compared in 15,799 first-degree
relatives of 5,047 patients with HL and 32,117 first-degree relatives of 10,078 control probands from
Sweden, and in 7,185 first-degree relatives of 2,429 patients with HL and 27,434 firstdegree relatives of
8,495 control probands from Denmark, using marginal survival models. An increased risk of HL in relatives
of patients with HL was observed in both populations, with relative risks of 3.47 (CI = 1.77–6.80) in
Sweden and 2.55 (CI = 1.01–6.45) in Denmark. In Sweden, familial risks were significantly increased for
chronic lymphocytic leukemia and non-Hodgkin lymphoma. Relative risks were higher in males than in
females and in siblings than in parents and offspring of patients. Relatives of patients with
earlier-onset disease were at higher risk for HL. Despite an important familial component for HL, the
cumulative lifetime risks in family members are very small. (Goldin LR, Pfeiffer RM, Gridley G, Gail
MH, Li X, Mellemkjaer L, Olsen JH, Hemminki K, Linet MS. Familial
aggregation of Hodgkin lymphoma and related tumors. Cancer 2004;100:1902-1908)
Occupation and Risk of Multiple Myeloma
A population-based case-control study in the U.S. was conducted to examine the relationship between
occupation, living or working on a farm, pesticide exposure, and the risk of multiple myeloma (MM). Among
573 persons newly diagnosed with MM and 2,131 controls, farmers and farm workers had odds ratios (OR) of
1.9 (CI = 0.8–4.6) and 1.4 (CI = 0.8–2.3), respectively. Sheep farm residents or workers had a slightly
increased risk of MM (OR = 1.7, CI = 1.0–2.7), but no increased risks were found for cattle, beef, pig, or
chicken farm residents or workers. A modestly increased risk was observed for pesticide exposure (OR =
1.3; CI = 0.9–1.8). Significantly increased risks were found for pharmacists, dietitians, and therapists
(OR = 6.1, CI = 1.7–22.5), service occupations (OR = 1.3; CI = 1.02–1.7), roofers (OR = 3.3; CI = 1.1–9.8),
precision printing occupations (OR = 10.1; CI = 1.03–99.8), heating equipment operators (OR = 4.7; CI =
1.4–15.8), and hand molders and casters (OR = 3.0; CI = 1.0–8.4). (Baris D, Silverman DT, Brown LM,
Swanson GM, Hayes RB, Schwartz AG, Liff JM, Schoenberg JB, Pottern LM, Greenberg RS, Stewart PA.
Occupation, pesticide exposure and
risk of multiple myeloma. Scand J Work Environ Health
2004;30:215-222)
INFECTIOUS AGENTS
Hepatitis C Infection and Non-Hodgkin Lymphoma
Studies have noted elevated hepatitis C virus (HCV) prevalence among patients with non-Hodgkin lymphoma
(NHL), but population-based data are lacking. Population-based case-control data from a U.S. study of NHL
were used to study HCV infection. Thirty-two of 813 (3.9 percent) NHL cases and 14 of 684 (2.1 percent)
controls were HCV infected (OR = 2.0; CI = 1.1–4.0). Although analyses of separate NHL subtypes were
based on limited numbers, positive associations were noted for follicular (OR = 2.54), marginal zone
(OR = 4.0), and mucosaassociated lymphoid tissue (OR = 2.0) NHLs. Adjustment for drug use and
transfusions did not affect the HCVNHL association. These results suggest an association between HCV
infection and NHL in the United States. (Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W,
Severson RK, Whitby D, Colt JS, Hartge P. Hepatitis
C virus infection and non-Hodgkin lymphoma: Results of the NCI-SEER
multi-center case-control study. Int J Cancer 2004:10;76-80)
Cancer among U.S. Army Veterans Exposed to SV40-contaminated Vaccines
Simian virus 40 (SV40) was a contaminant of vaccines produced in the 1950’s and early 1960’s, including a
parenteral adenovirus vaccine given to several hundred thousand U.S. military recruits. A casecontrol
study was conducted among male Army veterans to determine whether recruits receiving the SV40-contaminated
adenovirus vaccine had a higher risk of cancer. Among cases of brain tumors (n = 181), mesothelioma
(n = 10), and non-Hodgkin lymphoma (n = 220), the OR associated with exposure to SV40-contaminated adenovirus
vaccine were 0.8 (CI = 0.5–1.2) for brain tumors, 1.4 (CI = 0.4–5.1) for mesothelioma, and 1.0 (CI =
0.6–1.4) for non-Hodgkin lymphoma. These findings do not support a role for SV40 in the development of
these cancers. (Rollison DE, Page WF, Crawford H, Gridley G,Wacholder S, Martin J, Miller R, Engels
EA. Case-control study of cancer
among US Army veterans exposed to simian virus 40-contaminated adenovirus
vaccine. Am J Epidemiol 2004;160:317-324)
Maternal Poliovirus Vaccination and Risk of Childhood Cancer
To examine whether early-life simian virus 40 (SV40) infection can cause human cancer, 54,796 children
enrolled in the Collaborative Perinatal Project (CPP) were studied. Among this group, 52 children had
developed cancer by their eighth birthday. Children whose mothers had received pre-1963 poliovirus
vaccine during pregnancy (22.5 percent) had an increased incidence of neural tumors (hazard ratio [HR] =
2.6; CI = 1.0–6.7) and hematologic malignancies (HR = 2.8; CI = 1.2–6.4).Maternal serum samples were
tested for SV40 antibodies among CPP children with (n = 50) and without (n= 200) cancer. Mothers exhibited
infrequent, low-level SV40 antibody reactivity, and seroconversion during pregnancy was not consistently
related to children’s case/control status or mothers’ receipt of pre-1963 vaccine. The increased cancer
risk in CPP children whose mothers received pre-1963 poliovirus vaccine was unlikely to have been due to
SV40 infection transmitted from mothers to their children. (Engels EA, Chen J, Viscidi RP, Shah KV,
Daniel RW, Chatterjee N, Klebanoff MA. Poliovirus
vaccination during pregnancy, maternal seroconversion to simian virus
40, and risk of childhood cancer. Am J Epidemiol 2004;160:306-316)
LUNG CANCER
Antioxidant Intake and Risk of Lung Cancer
Higher intakes of individual antioxidants may protect against lung cancer. A dietary antioxidant index
was constructed that considered multiple antioxidants simultaneously to account for potential biochemical
interactions. This tool was used to predict lung cancer risk within the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study cohort. Among 27,111 Finnish male smokers, 1,787 incident cases of lung cancer
were identified. Principal components analyses were individually applied to the carotenoid, flavonoid,
and vitamin E nutrient groups, and summation of retained principal component scores, plus selenium and
vitamin C, yielded the composite antioxidant index. The relative risks for lung cancer according to
increasing quintiles of the antioxidant index were 1.00 (referent), 1.00 (CI = 0.87–1.14), 0.91 (CI =
0.79–1.05), 0.79 (CI = 0.68–0.92), and 0.84 (CI = 0.72–0.98) (p for trend = 0.002). These findings support
the hypothesis that a combination of dietary antioxidants reduces lung cancer risk in male smokers.
(Wright ME, Mayne ST, Stolzenberg-Solomon RZ, Li Z, Pietinen P, Taylor PR, Virtamo J, Albanes D.
Development of a comprehensive dietary
antioxidant index and application to lung cancer risk in a cohort of
male smokers. Am J Epidemiol 2004;1:68-76)
MALIGNANT MELANOMA
Toenail Arsenic Content and Cutaneous Melanoma
Because arsenic exposure has been linked to an increased risk of nonmelanoma skin cancer, a case-control
study in Iowa examined the association of arsenic with cutaneous melanoma among subjects aged 40 years or
older. Participants included 368 melanoma cases and 373 colorectal cancer controls diagnosed in 1999 or
2000. Participants completed a mailed survey and submitted toenail clippings for analysis of arsenic content
by graphite furnace atomic absorption spectrophotometry. There was an increased risk of melanoma for
persons with elevated toenail arsenic concentrations (OR = 2.1; CI = 1.4–3.3) and effect modification by
prior skin cancer diagnosis (p for interaction = 0.03). The arsenic-melanoma findings in this study are
new and thus warrant confirmation. (Beane-Freeman LE, Dennis LK, Lynch CF, Thorne PS, Just CL. Toenail
arsenic content and cutaneous melanoma in Iowa. Am J Epidemiol 2004;160:679-687)
Diet and Risk of Melanoma
Malignant melanoma has been one of the most rapidly increasing cancers within the United States. To
investigate the risk associated with dietary factors, newly diagnosed patients with melanoma (n = 502)
were compared with controls (n = 565). Persons in high versus low quintiles of energy-adjusted vitamin D,
alpha-carotene, beta-carotene, cryptoxanthin, lutein, and lycopene had significantly reduced risks for
melanoma, which remained after adjustment for presence of dysplastic nevi, education, and skin response
to repeated sun exposure. Micronutrients from supplements did not further reduce risk. High alcohol
consumption was associated with an increased risk for melanoma (OR = 1.6; CI = 1.1–2.5). Foods rich in
vitamin D and carotenoids as well as limited intake of alcohol may be associated with a lower risk of
melanoma. (Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D 4th, Holly EA, Sagebiel RW,
Potischman N. Diet and melanoma
in a case-control study. Cancer Epidemiol Biomarkers Prev
2004;13:1042-1051)
Genetic Susceptibility to Melanoma
Families (n = 55) from the northeastern region of Italy who were prone to melanoma and had at least two
relatives with melanoma were studied for genetic susceptibility markers.Multiple primary melanomas,
dysplastic nevi, and pancreatic cancer were present in several families. Three known p16 mutations—G101W,
R24P, and S56I—and a novel L65P were identified in four kindreds (7 percent of all families). The L65P
mutation caused a small distortion of p16 tertiary structure and reduced binding to CDK4 by 50 percent in
a yeast two-hybrid assay. No disease-related mutations were found in the other tested genes (CDKN2A,
CDKN2B, p14ARF), and there was no evidence for linkage to either chromosome 1 or 9. Germ line alterations
of one or more genes other than CDKN2A and on chromosome loci other than those previously identified may
be important for melanoma predisposition. (Landi MT, Goldstein AM, Tsang S, Munroe D, Modi W,
Ter-Minassian M, Steighner R, Dean M, Metheny N, Staats B, Agatep R, Hogg D, Calista D. Genetic
susceptibility in familial melanoma from northeastern Italy. J Med Genet 2004;41:557-566)
METHODS
Modeling Cancer Screening Disparities
Cancer screening rates vary substantially by race and ethnicity. The Peters-Belson approach, often used
in wage discrimination studies, was used to analyze disparities in cancer screening rates using the 1998
National Health Interview Survey. A regression model predicting the probability of getting screened was
fitted to the majority group and was used to estimate the expected values for minority group members had
they been members of the majority group. The covariates that explained the disparity in screening rates
for colorectal and breast cancer between the white and the black population did not explain the
disparity between the white and the Hispanic population (see Figure 3).
By understanding health disparities explained by measured covariates, more effective interventions and policies can be
developed. (Rao RS, Graubard BI, Breen N, Gastwirth JL. Understanding
the factors underlying disparities in cancer screening rates using
the Peters-Belson approach: Results from the 1998 National Health Interview
Survey. Med Care 2004;42:789-800)
OVARIAN CANCER
Infertility and Risk of Ovarian Cancer
To evaluate the risk of ovarian cancer as related to underlying causes of infertility, 12,193 women
evaluated for infertility between 1965 and 1988 were studied. Among this cohort, 45 ovarian cancers were
identified, showing a higher rate of ovarian cancer than the general female population (standardized
incidence ratio [SIR] = 2.0; CI = 1.4–2.6). The risk was higher for patients with primary infertility
(SIR = 2.7) than with secondary infertility (SIR = 1.4), particularly for those who never subsequently
conceived (SIR = 3.3). Women with endometriosis had the highest risk (SIR = 2.5; CI = 1.3–4.2).
Determination of ovarian cancer risk should take into account the type of infertility (primary versus
secondary) and underlying causes. Further study of endometriosis may provide insights into ovarian
carcinogenesis. (Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE,Westhoff CL. Ovarian
cancer risk associated with varying causes of infertility. Fertil Steril 2004;82:405-414)
|
![Return to Top](nov04/top.gif)
|
![DCEG People in the News](nov04/people.gif) |
Michael Alavanja, Dr.P.H., Occupational and Environmental Epidemiology Branch (OEEB), gave an invited talk on "Lung cancer incidence in the
Agricultural Health Study" at the Toxicology Forum in Aspen, Colorado, in June. Dr. Alavanja also gave related talks at the University of Trnava,
Slovakia, in July and at the International Society of Environmental Epidemiology in New York City in August.
Juan Alguacil, M.D., Ph.D. (OEEB), codirected and lectured in a course on "Use of biomarkers in epidemiological studies: Sample size,
sensitivity analysis, Hardy-Weinberg equilibrium and gene environment interactions" in Barcelona, Spain in June.
Blanche Alter, M.D., Clinical Genetics Branch (CGB), was invited to speak on "Cancer-prone rare genetic syndromes: How do they instruct us?"
at the Children's Hospital of Philadelphia in April and at the M.D. Anderson Cancer Center in Houston in September. Dr. Alter also spoke on "How do we
identify individuals with Diamond-Blackfan anemia?" at the Fifth International Diamond-Blackfan Anemia Consensus Conference held during April in New
York City.
Dalsu Baris, M.D., Ph.D. (OEEB), spoke on "Epidemiology of multiple myeloma" at the International Myeloma Foundation's Scientific Advisors
Retreat in Bermuda in May. Dr.Baris also cochaired a session on evaluating molecular testing and epidemiology.
Andre Bouville, Ph.D., Radiation Epidemiology Branch (REB), organized the section on "Radiation effects" for the 11th Congress of the
International Radiation Protection Association held in Madrid, Spain, in May. The Congress was attended by about 1,200 persons from 50 countries.
Other REB participants included Elaine Ron, Ph.D., who chaired a plenary session on "What is known about radiation effects at low doses?";
Martha Linet, M.D., who delivered a paper on the risks of hematopoietic and lymphoproliferative malignancies among U.S. radiologic
technologists; and Steven Simon, Ph.D., who gave a poster presentation on the estimation of the doses received by U.S. radiologic technologists.
Beth Brown, Ph.D., Viral Epidemiology Branch (VEB), has been appointed as a DCEG representative to the NIH Fellows Committee. She joins
Margaret Wright, Ph.D., of the Nutritional Epidemiology Branch (NEB).
Capt. Linda Morris Brown, Dr.P.H., Biostatistics Branch (BB), received the Robert Brutsche Award in August at the Annual Board Dinner of the
Commissioned Officers Association (COA). This award is presented each year to a current or past member in recognition of contributions to COA.
Capt. Brown served as the Health Services category representative to the COA Board of Directors from 1998 to 2002 as a member of the Executive
Committee and as Board Chair. She also chaired the Chief Professional Officer Forum at the Health Services Category Day during the PHS Professional
Conference held in May in Anchorage, Alaska. Capt. Brown was deployed with the PHS-1 Disaster Medical Assistance Team during the Reagan funeral
activities in June. She also gave an invited presentation on "The epidemiology of alcohol-associated cancers" at the National Institute on Alcohol
Abuse and Alcoholism symposium entitled Mechanisms of Alcohol-associated Cancer, held in October in Bethesda.
Nilanjan Chatterjee, Ph.D.(BB), delivered an invited presentation, "Novel conditional-likelihoods for exploiting gene-environment independence
in family-based case-control studies" in May at the International Conference on Analysis of Genomic Data in Boston and in June at the International
Conference on Statistics in the Health Sciences in Nantes, France. He also spoke on "Missing data problem in statistical genetics" in August at the
Workshop on Missing Data Problems held at the Fields Institute for Research in Mathematical Sciences in Toronto.
Joanne Colt, M.P.H., M.S. (OEEB), won first place for the overall outstanding poster at the American College of Epidemiology meeting held in
Boston in September. Ms. Colt's poster was titled "Organochlorines in carpet dust and non-Hodgkin lymphoma risk."
Wong-Ho Chow, Ph.D. (OEEB), was honored as a 2004 NCI Mentor of Merit at the annual NCI award
ceremony held in October. Mentor award winners, who are nominated by their trainees, received the highest
ranking in a competitive review by an advisory committee of postdoctoral fellows. The annual award
recognizes NCI investigators who have proven exceptional in their commitment to fostering the independent
careers of fellows, students, and other trainees.
Joseph Fraumeni, Jr., M.D., Director, DCEG, gave the keynote address on “Cancer among Native
Americans: An epidemiologic perspective” at the Conference on Changing Patterns of Cancer in Native
Communities in Phoenix during September.
Mark H. Greene, M.D. (CGB), gave an invited talk on “Indications for genetic testing” at the
American Society for Clinical Oncology symposium on Cancer Genetics in Practice: Current Guidelines,
Emerging Issues held in June in Chicago. Dr. Greene also spoke on “Prophylactic oophorectomy—surgical
risk reduction in hereditary ovarian cancer” at New York University’s Lynne Cohen Foundation Symposium on
the Emerging Role of Screening and Prevention in Women’s Cancer held in April in New York City.
Michael Hauptmann, Ph.D. (BB), organized and chaired a mini-symposium on Formaldehyde and Cancer
during the 17th International Symposium on Epidemiology in Occupational Health in Melbourne, Australia in
October. Dr. Hauptmann gave a talk during the mini-symposium. He also spoke on “Cancer mortality among
industrial workers exposed to formaldehyde” at the University of Washington, Seattle in April. He was a
member of the Working Group for the IARC Monograph on “Formaldehyde, 2-butoxyethanol and propylene
glycol mono-t-butyl ether” held in Lyon, France during June.
Richard Hayes, D.D.S., Ph.D. (OEEB), cochaired a meeting on molecular epidemiology entitled
“Linking toxicology to epidemiology: Biomarkers and new technologies” in Porvoo, Finland in July.
Ann Hsing, Ph.D., Hormonal and Reproductive Epidemiology Branch (HREB), served on the
organizing committee for the Prostate Cancer Disparities: Science, Health Care, and Public Policy
conference held in September at George Washington University. Dr. Hsing also moderated a session on
demographic patterns of prostate cancer.
Jose Jeronimo, M.D. (HREB), received an NCI Technology Transfer Award for development of an
Internet system for organizing, storing, studying, and sharing colposcopic images and for use as a
research tool. The work was done in collaboration with HREB staff and with engineers from the National
Library of Medicine.
Peter Inskip, Sc.D. (REB), received a tenure appointment in July. Dr. Inskip holds a doctoral degree
in epidemiology from the Harvard School of Public Health and joined NCI as a postdoctoral fellow in 1989
before accepting a position as Associate Professor in the College of Veterinary Medicine at Texas A&M
University. He returned to NCI in 1998 and launched a series of complex interdisciplinary studies in both
the U.S. and abroad. With meticulous attention to study design and innovative methods, Dr. Inskip developed
a research program that has provided new clues to the etiology of brain tumors, added to quantitative
understanding of the risks of radiation-induced cancer, generated insights into possible carcinogenic
mechanisms, and shaped the thinking and direction of research in these areas. Dr. Inskip initiated a
study to address public and Congressional concerns about whether the radio-frequency radiation emitted
by cellular telephones might cause brain cancer—a study which also explored a wide range of hypotheses
about the etiology of these poorly understood and often fatal tumors. The study resulted in a highly
publicized article in the New England Journal of Medicine that found no evidence of increased risk of
glioma, meningioma, or vestibular schwannoma associated with use of cellular phones. Dr. Inskip was
awarded an NIH Merit Award in 2001 in recognition of this work. In addition, Dr. Inskip founded and
directs the Radiation Epidemiology Fellowship Program to help foster the recruitment of young
investigators with expertise in the study of radiation-related cancer.
Martha Linet, M.D. (REB), gave an invited talk on “The effect of HIPAA privacy rule on research
studies” at the American College of Epidemiology (ACE) meeting held in Boston in September. Dr. Linet
also stepped up from presidentelect to president of ACE at the meeting.
Thomas O’Brien, M.D. (HREB), chaired a spotlight session and a roundtable discussion, each on
infectious disease epidemiology, at the Annual Meeting of the Society for Epidemiologic Research held in
June in Salt Lake City.
Arthur Schatzkin, M.D., Dr.P.H. (NEB), spoke on “Diet and cancer: A role for molecular
epidemiology?” at the United Kingdom Molecular Epidemiology Conference held in Cumbria, U.K. in
September. Dr. Schatzkin also spoke on “The NIH-American Association for Retired Persons (AARP) Diet and
Health Study: Physical activity and breast cancer” at the AARP national event held in Las Vegas in
October. He also was invited to speak on “Surrogate end points” at the American Association for Cancer
Research meeting on Frontiers in Prevention held in October in Seattle.
Mark Schiffman, M.D. (HREB), received the Food and Drug Administration’s Outstanding Service
Award in June as a member of the Human Papillomavirus DNA Cervical Cytology Screening Team in recognition
of his dedication to excellence in accomplishing the mission of the FDA.
Mark Sherman, M.D. (HREB), delivered the Warren Lang Lecture at the Thomas Jefferson University
School of Medicine in Philadelphia in April. Dr. Sherman spoke on “Management of endometrial carcinoma
precursors.”
Rashmi Sinha, Ph.D. (NEB), gave an invited talk on “Diet and cancer” at the Roche Research
Chapter of Sigma Xi in October at Hoffmann-La Roche, Inc. in Nutley, New Jersey. Dr. Sinha also spoke on
“Setting the bases for the creation of a database of substances formed during heat treatment” at the
European Cooperation in the Field of Scientific and Technical Research meeting on Thermally Processed
Foods: Possible Health Implications, held in October in Prague, Czech Republic.
Patricia Stewart, Ph.D. (OEEB), was invited to speak on “Issues for improving exposure
assessment in populationbased case-control studies” at the X2004 Conference in Utrecht, The Netherlands
in June. At the same meeting, Dr. Stewart chaired a mini-symposium on industrial hygiene databases and
chaired a session on self-reported and self-assessment of occupational exposures.
Rachael Stolzenberg-Solomon, Ph.D. (NEB), spoke on “Dietary folate intake, alcohol and
postmenopausal breast cancer risk” at the Society for Epidemiologic Research meeting held in June in
Salt Lake City.
Margaret Tucker, M.D., Genetic Epidemiology Branch (GEB), spoke on “The epidemiology of melanoma:
A case-control study” at the 12th Annual Meeting of the PanAmerican Society for Pigment Cell Research
held in Newport Beach, California, in June 2004.
Roel Vermeulen, Ph.D. (OEEB), chaired a session on “Dermal exposure to powders” at the X2004
Conference in Utrecht, The Netherlands in June.
Sholom Wacholder, Ph.D. (BB), gave an invited talk on “When can we believe results of molecular
epidemiology studies?” at the American College of Epidemiology meeting in Boston in September. Dr.
Wacholder also served as a discussant for a symposium on sensitivity analysis at the same meeting.
Mary Ward, Ph.D. (OEEB), chaired a symposium on Drinking Water Nitrate and Health at the
International Society of Environmental Epidemiology in New York City in August.
|
UPDATE ON RADIOLOGIC TECHNOLOGISTS STUDY
The U.S. Radiologic Technologists Study (USRT), the largest health study of
medical radiation workers ever conducted, is preparing to launch a third participant survey. In preparation,
study investigators, which include Radiation Epidemiology Branch members, collaborators at the University
of Minnesota, and members of the American Registry of Radiologic Technologists, have published the second
USRT newsletter. The newsletter presents information on recent research findings, an explanation of how
radiation doses are estimated, and a question-and-answer section.
The USRT study began in 1982 with the aim of quantifying the carcinogenic risks of long-term, low-dose,
fractionated radiation through occupation exposures and determining applicability of current risk
estimates, which are based primarily on studies of individuals experiencing single or short-term, high-dose
exposures, such as atomic bomb survivors and medically irradiated patients. More than 110,000
technologists are participating in the study. The USRT has developed a new web site
(http://www.radtechstudy.org) that includes information for study participants, researchers, and the general public.
|
![Return to Top](nov04/top.gif)
|
![Comings...Goings](nov04/comings.gif) |
Cara Frankenfeld, Ph.D., has joined the Nutritional Epidemiology Branch (NEB) as a cancer prevention
fellow. Dr. Frankenfeld earned an M.S. in nutritional sciences from the University of Arizona and a Ph.D. in
epidemiology from the University of Washington. During predoctoral and postdoctoral work at the Fred
Hutchinson Cancer Research Center, she evaluated markers of intestinal bacteria profiles in relation to
serum hormones, urinary estrogen metabolites, mammographic density, and bone mineral density in postmenopausal
women. She also evaluated the familial aggregation and segregation of these phenotypes as well as in vitro
studies on daidzein metabolism by intestinal bacteria. She is especially interested in the role played by
intestinal microbiota and specific nutrients, particularly flavonoids and other phenolic compounds, in
cancer risk.
Benjamin Hulley has joined the Genetic Epidemiology Branch (GEB) as a postbaccalaureate fellow.
Mr. Hulley graduated in June from the University of California, San Diego with a double major in cell
biology/biochemistry and management science (economics).During college, he worked as a research assistant on
a clinical trial of statins and conducted preliminary analyses of the data. Mr. Hulley also interned at
Genentech and worked as a laboratory technician in projects identifying genes contributing to susceptibility
to multiple sclerosis. During his time at GEB, Mr. Hulley plans to gain experience in various aspects of
conducting family- and population-based research into the determinants of cancer susceptibility.
Daehee Kang, M.D., Ph.D., an Associate Professor in epidemiology at the Seoul National University
College of Medicine, has joined the Occupational and Environmental Epidemiology Branch (OEEB) for a two-year
sabbatical under the auspices of the Oak Ridge Institute for Scientific Exchange. Dr. Kang holds an M.D.
from Seoul National University and a Ph.D. in environmental health sciences from Johns Hopkins University. He
is an experienced molecular and environmental epidemiologist with interests in cancer risks from exposure to
polycyclic aromatic hydrocarbons, solvents, and pesticides. While in the OEEB he will work on several
population cohort studies.
Gregory Kirk, M.D., Ph.D., completed a postdoctoral fellowship with the Viral Epidemiology Branch
(VEB) and accepted a position as Assistant Professor of Infectious Disease Epidemiology at the Johns Hopkins
Bloomberg School of Public Health. Dr. Kirk first joined VEB in 1996 as a Special Volunteer. He spent most
of 1997 through 1999 in Gambia,West Africa, where he launched and supervised the Gambia Liver Cancer Study of
hepatocellular carcinoma. From 1999 to 2003, while continuing to monitor work in Gambia, Dr. Kirk completed
a residency in internal medicine at Georgetown University, a clinical fellowship in infectious diseases at
the National Institute of Allergy and Infectious Diseases, and a doctoral degree in epidemiology from Johns
Hopkins University.Working with James Goedert, M.D., and Dr. Ruggero Montesano, Dr. Kirk used the data and
specimens from the Gambia Liver Cancer Study as the basis for his dissertation, “The epidemiology of viral,
environmental and genetic factors in hepatocellular carcinoma: A case-control study from The Gambia, West
Africa.” Dr. Kirk served on the DCEG Technical Evaluation of Questionnaires committee and as coordinator of
VEB’s hepatocellular carcinoma working group.
Cari Kornblit has joined the Office of the Director as a health communications fellow. Ms. Kornblit
received her undergraduate degree in biology from New York University (NYU) in 1999 and is currently pursuing
a master’s degree in professional writing with a specialization in science and medical communications at
Carnegie Mellon University in Pittsburgh. Before venturing into writing, she worked in molecular biology
research for more than six years. During that time, Ms. Kornblit received an independent research grant from
Children’s Hospital of Pittsburgh and worked in laboratories at NYU and, most recently, at the University of
Pittsburgh, where she managed and conducted research in a molecular cardiology laboratory. She will be
working with Betsy Duane-Potocki on various communication projects.
Ola Landgren, M.D., Ph.D., has joined GEB as a visiting fellow. A native of Stockholm, Sweden, Dr.
Landgren received his medical and doctoral degrees from the Karolinska Hospital and Institute in Stockholm.
For his thesis, he studied diagnostic and prognostic characteristics in Hodgkin lymphoma patients with
special reference to the elderly. He is a board-certified specialist in hematology, internal medicine, and
pain management and holds a consultant position at the Karolinska Hospital. Dr. Landgren will be collaborating
with Lynn Goldin, Ph.D., Neil Caporaso, M.D., and Mary McMaster, M.D., on studies related to
familial lymphoproliferative tumors and precursor conditions.
Karla Lawson, Ph.D., a cancer prevention fellow, has joined the NEB. Dr. Lawson received a Ph.D. in
nutritional sciences from the University of Texas at Austin in 2003. She earned a Bachelor of Science degree
in nutrition from the University of Texas at Austin in 1998, where she completed the registration exam and
was certified as a registered dietitian. In 2004, she received an M.P.H. from Johns Hopkins University,
concentrating in biostatistics and epidemiology. Her master’s research examined the interaction between estimated
calcium intake and a polymorphism in the vitamin D receptor on prostate cancer risk. Dr. Lawson’s current
interests include the effects of supplemental and dietary vitamin E on cancer risk and prevention.
Annette Molinaro, Ph.D., has joined the Biostatistics Branch (BB) as a cancer prevention fellow. Dr.
Molinaro received her master’s and doctoral degrees in biostatistics from the University of California,
Berkeley. Her dissertation involved predicting survival outcomes with high-dimensional explanatory variables.
During her fellowship she will continue exploring new algorithms for building predictors with genomic and
proteomic data. In addition, Dr.Molinaro will compare cross-validation techniques for model selection and
assessment in small sample sizes.
Lindsay Morton, Ph.D., has joined the Hormonal and Reproductive Epidemiology Branch (HREB) as a
postdoctoral fellow. Dr.Morton recently received her doctoral degree in epidemiology from Yale University,
where her dissertation research focused on the association between hepatitis C and non-Hodgkin lymphoma
(NHL). She also conducted the first pooled analysis of smoking, alcohol, and NHL risk in InterLymph, the
international consortium of lymphoma case-control studies. Dr.Morton also worked in the Yale Emerging
Infections Program conducting research on chronic liver disease and conducted clinical trials at the
Massachusetts General Hospital. While at DCEG, she plans to pursue her interests in viral, genetic, and
hormonal etiology of cancers.
Christine Mueller, D.O., has joined the Clinical Genetics Branch (CGB) as a clinical cancer genetics
fellow. Dr.Mueller comes to NCI from the University of Pittsburgh, where she was an Assistant Clinical
Professor in the Center for Medical Genetics, Department of Family Medicine. She received her degree in
medicine in 1998 from the Ohio University College of Osteopathic Medicine, where she also earned board
certification in family medicine. Dr. Mueller then completed a clinical medical genetics fellowship at the
University of Pittsburgh School of Medicine, and she is board eligible in medical genetics. She is formally
trained in dysmorphology and will be responsible for that aspect of patient care, data collection, and analysis
in CGB’s Inherited Bone Marrow Failure Syndromes study. She will also be developing new projects related to
hereditary breast/ovarian cancer, early detection of ovarian cancer, and familial bladder cancer.
Sue Kyung Park, M.D., Ph.D., has joined the HREB as a postdoctoral fellow. Dr. Park received her medical
degree from the Kyungpook National University of South Korea in 1991. She completed a radiation oncology
residency at the Asan Medical Center in 1994 and a preventive medicine residency at the Seoul National
University in 1997. After passing specialty boards in both preventive and occupational medicine, Dr. Park
received a Ph.D. from the Seoul National University in 1999, where her doctoral research involved genetic
polymorphisms and breast cancer risk. She is currently an Assistant Professor of Preventive Medicine at The
Konkuk University College of Medicine of South Korea. During her stay in HREB, Dr. Park plans to study the
role of endogenous hormones in the development of cancers in women.
Beata Peplonska, M.D., Ph.D., has joined OEEB as a special volunteer for one year. Dr. Peplonska
is Chief of the Epidemiological Unit at the Nofer Institute of Occupational Medicine in Lodz, Poland. She
has an M.D. from the Medical Academy in Lodz and a Ph.D. from the Nofer Institute. Dr. Peplonska is the
field director for the Lodz component of the Breast, Ovary, and Endometrial Cancer Study in Poland led by
Louise Brinton, Ph.D., and Montserrat Garcia-Closas, M.D., Dr.P.H. She will analyze data on occupational
exposures and breast cancer during her stay in DCEG.
Sowmya Rao, Ph.D., a postdoctoral fellow in BB since 2001, has accepted a survey position with Abt
Associates in Cambridge, Massachusetts. While in DCEG, she developed methods to adjust for missing data in
the analysis of standardized incidence ratios and applied these methods to an analysis of the X-Ray
Technologists Study. Using the National Health Interview Survey, Dr. Rao developed and applied methods to
evaluate racial/ethnic disparities in cancer screening rates. She also analyzed data collected from NIH
postdoctoral fellows to evaluate NIH-wide mentoring.
Katherine Roberts, a predoctoral fellow in NEB since 2003, has left to begin her Ph.D. in chronic
disease epidemiology at Johns Hopkins Bloomberg School of Public Health. While in DCEG, Ms. Roberts completed
her M.P.H. and worked with Rachael Stolzenberg-Solomon, Ph.D., on a literature review of studies examining
weight loss and hormone changes in women. She also conducted analyses on one-carbon polymorphisms in the Navy
colorectal polyps study and on characteristics of the insulin resistance syndrome and colorectal cancer.
Monica Ter-Minassian, M.S., who had been a predoctoral fellow in GEB since 2002, has left to enter
the doctoral program at the Harvard School of Public Health. Ms. Ter-Minassian’s ultimate goal is to focus on
genetic and molecular epidemiology in the field of cancer research. During her time in DCEG, she worked with
Lynn Goldin, Ph.D., and Maria Landi, M.D., Ph.D., on linkage analysis within the Italian familial melanoma
study.
Isabelle Thierry-Chef, Ph.D., has joined the Radiation Epidemiology Branch as a postdoctoral fellow.
Dr. Thierry-Chef previously worked as a research scientist at the Institute for Radiation Protection and
Nuclear Safety (IRSN) in France and received her Ph.D. in environmental science from the University of
Provence, France. Her doctoral research, which was conducted at the International Agency for Research on
Cancer, involved the study of errors in dosimetry within an international collaborative study of cancer risk
among workers in the nuclear industry. At ISRN, Dr. Thierry-Chef conducted a feasibility study of health
effects resulting from multiple x-rays among a population of premature babies. While at REB, she hopes to
conduct a similar feasibility study in the U.S. and gain experience in the assessment of uncertainties
associated with medical, occupational, and environmental exposures.
Robin Wilson, Ph.D., a postdoctoral fellow in OEEB since 2002, has taken a position as Assistant
Professor in the Department of Health Sciences at the Hershey Medical Center, Pennsylvania State College of
Medicine. During her fellowship, Dr.Wilson analyzed occupational risks of salivary gland tumors, used
geographic information system approaches in epidemiologic studies, and participated in studies of second
primaries among cancer survivors.
Yawei Zhang, M.D., Ph.D., has joined HREB as a postdoctoral fellow. Dr. Zhang received a Doctor of
Medicine degree from West China University of Medical Sciences and an M.P.H. and Ph.D. (epidemiology) from
Yale University. For her doctoral dissertation, Dr. Zhang investigated the association between non-Hodgkin
lymphoma (NHL) and a variety of exposures, including farm and nonfarm use of pesticides, use of haircoloring
products, and ultraviolet exposure from sun and other sources. Dr. Zhang also investigated gene-environment
interactions as related to risks of lymphoma, breast cancer, and multiple myeloma.While at DCEG, she plans
to pursue her interests in testicular cancer and NHL.
|
DCEG EXPANDS INTRAMURAL RESEARCH AWARD PROGRAM
In order to provide more competitive funding opportunities for fellows and
tenure-track scientists, DCEG has expanded its Intramural Research Award (IRA) program to two yearly
funding cycles: one in the spring and one in the fall. Each cycle will fund up to three proposals.
The IRA program recognizes small, innovative, interdisciplinary research projects being led by
tenure-track investigators and fellows in the Division. These projects often cross usual organizational
boundaries. Individuals are eligible to receive up to $75,000 a year in research funds, and the award
is renewable for up to three years. Each proposal is reviewed by a member of the NCI Board of Scientific
Counselors or another extramural scientist with appropriate expertise and by senior DCEG scientists. The
proposals are judged on potential for significant scientific or public health impact, innovative aspects
of the approach or methodology, interdisciplinary and collaborative nature of the project, ability to
achieve the objectives within the proposed time frame and with the proposed resources, and programmatic
relevance to the Division. The award can be combined with funds from other sources to support a larger
project.
|
![Return to Top](nov04/top.gif)
|
![David Pawel Receives Beebe Fellowship](nov04/pawel.gif) |
Dr. David Pawel, a statistician in the Radiation Protection Division of the
Environmental Protection Agency (EPA), recently completed the Beebe Fellowship. The fellowship honors
Gilbert Wheeler Beebe, Ph.D. (1912–2003), a renowned radiation epidemiologist who conducted
groundbreaking studies of mortality and morbidity among persons exposed to the atomic bombings in Japan and
to the Chernobyl reactor accident in Ukraine and who spent the last 25 years of his career working at NCI.
During the fellowship, scientists spend time working at the Radiation Epidemiology Branch (REB) and the
Radiation Effects Research Foundation (RERF) in Hiroshima, Japan, on research related to the atomic bomb
survivors and other radiation topics.
Dr. Pawel, who holds a doctoral degree in statistics from the University of Wyoming, had spent a few
early years in his career (1992–1994) working at the RERF. “The Beebe Fellowship not only allowed me to
work at RERF again, but provided another opportunity to take advantage of the relationship between our
center and REB,” said Dr. Pawel.
During his first tour at the RERF, he worked with two prominent cytogeneticists, Dr. Akio Awa and Dr.
Nori Nakamura, and others on using frequency of stable chromosome aberrations to validate the reconstructed
radiation dose estimates that underlie estimates of dose-related cancer risk. Their study showed a lower
dose response for stable chromosome aberrations among Nagasaki factory workers than other atomic bomb
survivors, suggesting that doses for the factory workers may have been substantially overestimated. The
finding contributed new insights into comparisons of dose response between Hiroshima and Nagasaki.
Through the Beebe Fellowship, Dr. Pawel returned to work at RERF from September to December of 2003. “I
decided to work on a problem relating to the estimation of site-specific cancer risks, ”explained Dr. Pawel.
His interest stemmed in part from a talk given by Dr. Donald Pierce, who noted that among women the fitted
site-specific mortality risks for solid cancers (1950–90) did not vary significantly by cancer site. During
the Beebe Fellowship, Dr. Pawel was able to show that simple “shrinkage estimates” may improve estimates of
site-specific risks derived from cancer incidence data among atomic bomb survivors.
From February through April 2004, Dr. Pawel split his time between EPA and NCI. At NCI, he worked with
Charles Land, Ph.D. (REB), to investigate the feasibility of applying his RERF work to improve a
computer program that calculates radiogenic risks. “I enjoyed very much working at NCI, and though I still
have much to do on this project, I look forward to a continued collaboration with REB,” said Dr. Pawel.
The Beebe Fellowship is sponsored by the Department of Energy, National Academy of Sciences, NCI, and
RERF. It is intended for mid- to senior-level epidemiologists or biostatisticians and allows great
flexibility in working arrangements.More information can be found at http://dceg.cancer.gov/reb/fellowships/beebefellowship.
—Maria Sgambati, M.D.
|
ARRIVEDERCI A MARIA
Maria Sgambati, M.D. (OD), editor of Linkage, has transferred to the
Division of Cancer Prevention as a Program Director in the Community Oncology and Prevention Trials
Research Group. In her new job, she will work with the Community Clinical Oncology program, which
coordinates the conduct of NCI-funded clinical trials in community practices. Since 2002, Dr. Sgambati
has been the managing editor of Linkage and performed various other writing and editing tasks.
Before that she was a clinical research fellow in GEB. Maria Sgambati During her tenure as editor,
circulation grew and the newsletter improved in content and appearance while providing interesting
highlights of the science and staff of DCEG.
|
![Return to Top](nov04/top.gif)
|